Astria Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $20.00 price target.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Astria Therapeutics’ clinical program. The initiation of the Phase 3 ORBIT-EXPANSE long-term trial for navenibart, a monoclonal antibody inhibitor targeting plasma kallikrein for hereditary angioedema (HAE) patients, is a significant milestone. This trial aims to evaluate the long-term safety and tolerability of navenibart, following the completion of the Phase 3 ALPHA-ORBIT study.
The structured design of the ORBIT-EXPANSE trial, which allows for flexible dosing regimens, underscores the potential of navenibart as a leading prophylactic treatment in the HAE market. The anticipated topline data from the ALPHA-ORBIT study in early 2027 further supports the optimism surrounding navenibart’s efficacy in reducing attack rates. These factors collectively contribute to the confidence in navenibart’s potential to become a first-choice treatment option, justifying the Buy rating.
In another report released on October 1, Evercore ISI also maintained a Buy rating on the stock with a $26.00 price target.